Primecap Management
WVE icon

Primecap Management’s Wave Life Sciences WVE Stock Holding History

Primecap Management’s Portfolio WVE Stock Details WVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35M Buy
4,832,952
+737,670
+18% +$9.61M 0.03% 209
2025
Q4 		$69.6M Buy
4,095,282
+2,196,632
+116% +$22.3M 0.05% 178
2025
Q3 		$13.9M Sell
1,898,650
-567,200
-23% -$4.59M 0.01% 249
2025
Q2 		$16M Sell
2,465,850
-41,670
-2% -$275K 0.01% 250
2025
Q1 		$20.3M Sell
2,507,520
-12,000
-0.5% -$131K 0.02% 231
2024
Q4 		$31.2M Sell
2,519,520
-61,180
-2% -$817K 0.02% 214
2024
Q3 		$21.2M Sell
2,580,700
-83,516
-3% -$499K 0.02% 229
2024
Q2 		$13.3M Sell
2,664,216
-212,224
-7% -$1.21M 0.01% 248
2024
Q1 		$17.7M Sell
2,876,440
-882,968
-23% -$4.42M 0.01% 234
2023
Q4 		$19M Sell
3,759,408
-21,100
-0.6% -$113K 0.02% 229
2023
Q3 		$21.7M Sell
3,780,508
-30,900
-0.8% -$141K 0.02% 225
2023
Q2 		$13.9M Sell
3,811,408
-369,700
-9% -$1.49M 0.01% 245
2023
Q1 		$18.1M Sell
4,181,108
-8,500
-0.2% -$38.9K 0.02% 230
2022
Q4 		$29.3M Sell
4,189,608
-220,300
-5% -$1.02M 0.03% 198
2022
Q3 		$15.9M Sell
4,409,908
-16,900
-0.4% -$56K 0.02% 219
2022
Q2 		$14.4M Sell
4,426,808
-134,467
-3% -$259K 0.01% 233
2022
Q1 		$9.12M Sell
4,561,275
-33,300
-0.7% -$81.6K 0.01% 265
2021
Q4 		$14.4M Buy
4,594,575
+25,600
+0.6% +$106K 0.01% 253
2021
Q3 		$22.4M Sell
4,568,975
-18,591
-0.4% -$113K 0.02% 237
2021
Q2 		$30.6M Sell
4,587,566
-78,384
-2% -$512K 0.02% 220
2021
Q1 		$26.2M Buy
4,665,950
+741,475
+19% +$7.12M 0.02% 227
2020
Q4 		$30.9M Buy
3,924,475
+623,080
+19% +$5.23M 0.02% 211
2020
Q3 		$28M Buy
3,301,395
+1,985,241
+151% +$21.8M 0.02% 201
2020
Q2 		$13.7M Buy
1,316,154
+80,566
+7% +$758K 0.01% 221
2020
Q1 		$11.6M Sell
1,235,588
-58,132
-4% -$495K 0.01% 212
2019
Q4 		$10.4M Buy
1,293,720
+464,219
+56% +$11.4M 0.01% 235
2019
Q3 		$17M Buy
+829,501
New +$19M 0.01% 211

Other funds holding WVE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
GP
GSK plc London $599M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

Primecap Management's WVE Position: Q1 2026 in Review

Primecap Management increased its Wave Life Sciences (WVE) stake by 18% in Q1 2026, buying an estimated $9.61M and bringing the position to 4,832,952 shares worth $35M. The position accounts for 0.03% of the portfolio, ranked #209.

Primecap Management first reported a position in WVE in Q3 2019 and has held it in 27 quarters since. The position peaked at $69.6M in Q4 2025. 230 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

  • Primecap Management held 4,832,952 shares of Wave Life Sciences worth $35M as of Q1 2026.
  • Primecap Management bought 737,670 Wave Life Sciences shares in Q1 2026, an estimated $9.61M.
  • Wave Life Sciences made up 0.03% of Primecap Management's portfolio in Q1 2026, its #209 holding.
  • Primecap Management first reported a position in Wave Life Sciences in Q3 2019 and has held it in 27 quarters since.
  • Primecap Management's Wave Life Sciences position peaked at $69.6M in Q4 2025.
  • 230 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Primecap Management's 13F filing for Q1 2026, filed 11 May 2026.